Health Condition 1: F028- Dementia in other diseases classified elsewhere
Conditions
Interventions
Intervention1: Pioglitazone: 15mg Once daily for 6 months
Control Intervention1: Placebo: Placebo once daily for 6 months
Sponsors
None
Eligibility
Inclusion criteria
Inclusion criteria: Patients with cognitive impairment (MoCA scale below 26) Individuals willing to participate in the study Patients on standard therapy managing their neurological conditions
Exclusion criteria
Exclusion criteria: Patients on insulin medication Uncontrolled hypertension (SBP above150/90 mm/Hg) Patients with bladder cancer, kidney, liver and heart complications Osteoporosis patients or those at high risk of fractures • Contraindicated medication usage • The participant has a known history of hypersensitivity to pioglitazone • Has a history or current diagnosis of macular edema or macular degeneration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measures will be changes in MoCA Score and amyloid beta 42 40 ratio before and after the treatment.Timepoint: Time points will be the 2nd month, 4th month, 6th month and at 12th month | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcome will be change in EEG-P300 wave, assessment of adverse drug reactions (ADRs), quality of life and medication adherence after every 2 monthsTimepoint: Time points will be the 2nd month, 4th month, 6th month and at 12th month | — |
Countries
India
Contacts
Public ContactDr S Robert Wilson
SRM Institute of Science and Technology, Kattankulathur
Outcome results
None listed